Want to see SBC full AI Analyst Report?
Top Page
SBC Medical Group Holdings
(NASDAQ:SBC)
Select Model
Select Model
Rating:83Outperform
Price Target:
$4.50
▲(47.06% Upside)
Action:Reiterated
Date:08/20/26
The score is driven primarily by strong financial performance (high margins, strong recent cash generation, and low leverage) and a favorable valuation (low P/E). Technicals are supportive but show stretched momentum (high RSI/Stoch), and earnings-call commentary adds upside from network expansion and AI initiatives while highlighting execution and concentration risks.
Positive Factors
Clinic Network and Customer Growth
Expanding clinic capacity alongside higher patient visits supports durable revenue growth and improves network scale. Same-clinic revenue growth and higher spending per visit also indicate that expansion is being supported by stronger underlying clinic productivity.
Negative Factors
Volatile Revenue and Cash Conversion
Recent acceleration is encouraging, but prior revenue declines and uneven cash generation show that demand and earnings quality have not been consistent across cycles. This may make long-term planning less predictable and increase reliance on continued execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinic Network and Customer Growth
Expanding clinic capacity alongside higher patient visits supports durable revenue growth and improves network scale. Same-clinic revenue growth and higher spending per visit also indicate that expansion is being supported by stronger underlying clinic productivity.
Read all positive factors
SBC Medical Group Holdings (SBC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$411.39M
Dividend YieldN/A
Average Volume (3M)65.67K
Price to Earnings (P/E)8.5
Beta (1Y)0.60
Revenue Growth-6.92%
EPS Growth46.87%
CountryUS
Employees863
SectorIndustrials
Sector Strength72
IndustryConsulting Services
Share Statistics
EPS (TTM)0.47
Shares Outstanding102,846,950
10 Day Avg. Volume48,167
30 Day Avg. Volume65,672
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)1.79
Price to Sales (P/S)2.56
P/FCF Ratio12.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.50Price Target Upside177.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.48
Revenue Forecast (FY)$187.35M
SBC Medical Group Holdings Business Overview & Revenue Model
Company Description
SBC Medical Group Holdings Incorporated provides comprehensive operational support to aesthetic and cosmetic clinics across a global footprint, including Japan, Vietnam, the United States, and other international markets. The company delivers a di...
How the Company Makes Money
SBC Medical Group Holdings primarily makes money by providing fee-for-service elective aesthetic medical treatments through its clinics, generating revenue from patient payments for procedures, treatments, and related services. Revenue is driven b...
SBC Medical Group Holdings Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Positive
The call conveyed multiple strong operational and financial improvements: double-digit revenue growth, a 32% rise in adjusted EBITDA and margin expansion to 41%, network expansion (+34 locations YoY), rising customer metrics, clear multi-brand and AI-driven strategies, and actionable international initiatives. Challenges flagged were manageable in the near term (one-time SG&A items, currency headwind) and longer-term execution risks around AI rollouts, international scaling and diversification away from aesthetic services. On balance, the positives (strong growth, profitability gains, AI and product/brand initiatives, ample capital for disciplined M&A) materially outweigh the noted challenges.Positive Updates
Strong Top- and Bottom-Line Growth
Q2 revenue of $49M, up 13% year-over-year; Adjusted EBITDA $20M, up 32% YoY, yielding an adjusted EBITDA margin of 41% — profit growth outpaced revenue growth.
Negative Updates
SG&A Higher Than Expected
SG&A rose slightly versus expectations; management attributed much of the increase to one-time costs related to a secondary offering, though near-term expense pressure was noted.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Top- and Bottom-Line Growth
Q2 revenue of $49M, up 13% year-over-year; Adjusted EBITDA $20M, up 32% YoY, yielding an adjusted EBITDA margin of 41% — profit growth outpaced revenue growth.
Read all positive updates
Company Guidance
The company guided to a reacceleration of growth supported by network expansion, AI-driven service upsell and international rollouts, backing that with many concrete metrics: as of June 2026 SBC had 287 locations (up 34 YoY) and 6.92M trailing‑12‑month visits (up 10%); year‑to‑date clinic revenue rose 11%, same‑clinic revenue +6% and average spend per visit +9%; Q2 revenue was $49M (+13% YoY) with adjusted EBITDA $20M (+32%) and a 41% adjusted EBITDA margin. Management highlighted H1 transaction‑value growth of ~19% for key brands (Gorilla Clinic H1 transaction value $62M, +19%), a transaction mix ~84% aesthetic /16% non‑aesthetic, a target to raise average fee per clinic by roughly $15M/year from AI and call‑center initiatives ($11M call center, $4M Gorilla/Rize) (partial impact in H2, full contribution next fiscal year), OrangeTwist at 24 U.S. locations with >40% recurring revenue, a shareholder base ~4.7x larger YoY (July 2026), ~26 years of data fueling AI, net cash ~45% of market cap, and a long‑term goal of 1,000 clinics by 2035 (longevity center planned 2027).SBC Medical Group Holdings Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
86
Very Positive
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 175.17M | 173.61M | 205.42M | 193.54M | 174.16M |
| Gross Profit | 124.84M | 127.28M | 156.05M | 137.30M | 114.83M |
| EBITDA | 76.46M | 84.91M | 77.28M | 85.87M | 29.64M |
| Net Income | 49.03M | 50.99M | 46.61M | 39.37M | 6.32M |
Balance Sheet | |||||
| Total Assets | 406.66M | 380.45M | 266.08M | 258.81M | 225.48M |
| Cash, Cash Equivalents and Short-Term Investments | 184.62M | 164.09M | 125.04M | 103.02M | 53.64M |
| Total Debt | 48.23M | 51.64M | 12.21M | 22.87M | 16.13M |
| Total Liabilities | 126.74M | 117.14M | 71.06M | 115.00M | 117.63M |
| Stockholders Equity | 263.84M | 248.28M | 195.11M | 142.16M | 105.25M |
Cash Flow | |||||
| Free Cash Flow | 74.96M | 36.55M | 17.17M | 39.44M | -24.99M |
| Operating Cash Flow | 77.07M | 38.92M | 20.58M | 50.64M | -47.37K |
| Investing Cash Flow | -36.33M | -20.97M | -10.10M | 1.82M | -32.65M |
| Financing Cash Flow | 13.33M | 24.04M | 22.97M | 6.14M | -7.98M |
SBC Medical Group Holdings Technical Analysis
Positive
3.06
Price Trends
3.15
Positive
3.32
Positive
3.66
Positive
Market Momentum
0.19
Negative
71.73
Negative
89.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBC, the sentiment is Positive. The current price of 3.06 is below the 20-day moving average (MA) of 3.31, below the 50-day MA of 3.15, and below the 200-day MA of 3.66, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 71.73 is Negative, neither overbought nor oversold. The STOCH value of 89.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SBC.
SBC Medical Group Holdings Risk Analysis
SBC Medical Group Holdings disclosed 79 risk factors in its most recent earnings report. SBC Medical Group Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Because we are not currently in compliance with certain Nasdaq corporate governance requirements, Nasdaq may delist our securities from trading on its exchange, which could limit investors' ability to make transactions in our securities and subject us to additional trading restrictions. Q2, 2026
SBC Medical Group Holdings Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | $411.39M | 8.51 | 19.31% | ― | -6.92% | 46.87% | |
67 Neutral | $1.11B | 23.28 | 24.76% | 1.30% | 11.46% | -9.16% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
57 Neutral | $229.15M | 112.72 | 4.33% | ― | -6.14% | -78.29% | |
56 Neutral | $36.24M | 14.25 | -113.55% | ― | 11.24% | ― | |
53 Neutral | $224.28M | -5.26 | -33.27% | ― | -7.54% | 52.04% | |
48 Neutral | $149.49M | -3.61 | -21.44% | 7.43% | -18.02% | 79.32% |
* Industrials Sector Average
SBC
SBC Medical Group Holdings
4.00
-0.13
-3.15%
CRAI
Cra International
176.90
-16.85
-8.70%
FORR
Forrester Research
11.78
1.91
19.35%
FC
Franklin Covey Company
20.29
0.94
4.86%
RGP
Resources Connection
4.34
-0.21
-4.68%
AERT
Aeries Technology
6.91
0.01
0.20%
SBC Medical Group Holdings Corporate Events
Business Operations and StrategyFinancial Disclosures
SBC Medical Group Posts Strong Q2 2026 Profit Rebound
Positive
Aug 13, 2026
On August 13, 2026, SBC Medical Group Holdings reported second-quarter 2026 results showing a sharp rebound in profitability following its 2025 restructuring, with revenue up 13% year-on-year to $49 million and net income attributable to the compa...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
SBC Medical Group Faces Nasdaq Compliance Governance Challenges
Negative
Jul 15, 2026
On July 8, 2026, at its Annual Meeting, SBC Medical Group Holdings lost compliance with Nasdaq’s independent director and audit committee rules following director Mike Sayama’s decision not to stand for re‑election, leaving the b...
Executive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
SBC Medical Announces Director Exit and Governance Transition
Neutral
May 20, 2026
On May 14, 2026, SBC Medical Group Holdings said independent director Mike Sayama will not seek re-election at its upcoming 2026 Annual Meeting of Stockholders, clarifying that his decision did not stem from any disagreement with the company, mana...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.